The findings could lead to a new drug target for developing less-addictive pain medications.
The research from the Kang and Lerner labs reveals new targets for treating cancer and autoimmune diseases.
“I’m grateful to the Gates Foundation for its strong support of our research and for its continued commitment to eradicating HIV/AIDS throughout the world,” says Professor Michael Farzan.
“I look forward to capitalizing on [Jamie and Doug’s] extensive experience to help realize our exciting vision for TSRI's future,” says President-Elect Steve Kay.